Normal Pap Smear with Inflammation: Evaluation and Management
A normal Pap smear showing inflammatory cells typically requires no immediate intervention, but if severe inflammation with reactive cellular changes is present, repeat the Pap smear in 3 months after treating any identifiable underlying infection. 1
Understanding the Finding
A Pap smear reported as "normal" or "negative for intraepithelial lesion or malignancy" (NILM) with inflammatory cells is a common finding that does not indicate cervical cancer or precancerous changes. The inflammatory cells represent a benign reactive process. However, the clinical significance depends on the degree of inflammation and associated findings.
Key Distinction: Degree of Inflammation Matters
The management pathway differs based on severity:
Mild to Moderate Inflammation
- No specific follow-up required beyond routine screening intervals 1
- Continue regular Pap smears according to age-appropriate guidelines (typically every 3 years for ages 21-65, or every 5 years with co-testing for ages 30-65)
- The Pap smear is not a screening test for STDs 2
Severe Inflammation with Reactive Cellular Changes
- Repeat Pap smear in 3 months 1
- If possible, identify and treat underlying infection before the repeat smear
- This approach prevents missing dysplastic changes that may be obscured by severe inflammation
Evaluation for Underlying Infections
While inflammation on Pap smear does not reliably predict specific infections (research shows only 60% correlation with positive cultures in asymptomatic women 3), consider evaluation if:
- Clinical symptoms are present: vaginal discharge, cervical mucopurulent discharge, contact bleeding, or pelvic pain
- Cervical examination is abnormal: visible cervicitis, mucopus, or cervical erosion
- Patient is in a high-risk setting: STD clinic population or multiple risk factors
Testing to consider when clinically indicated:
- Cervical cultures or nucleic acid amplification tests for Chlamydia trachomatis and Neisseria gonorrhoeae
- Wet mount or testing for Trichomonas vaginalis
- Evaluation for bacterial vaginosis
- Consider herpes simplex virus testing if ulcerations present
Important Caveats and Pitfalls
Do not empirically treat inflammation without identified pathogen. Research demonstrates that empiric metronidazole treatment for inflammatory Pap smears shows no benefit in resolving cytologic changes 4. Treatment should be directed at specific identified organisms.
Do not defer the Pap smear unnecessarily. While older guidelines suggested deferring Pap smears in the presence of obvious severe cervicitis until after treatment 1, current practice recognizes that most Pap smears remain satisfactory for evaluation even with infection present 2. The presence of mucopurulent discharge should not delay the Pap test—it can be performed after careful removal of discharge with a saline-soaked swab 2.
Be aware of persistent inflammation. If inflammation persists on repeat Pap smears despite treatment of identified infections, research suggests 16-53% of these women may harbor cervical intraepithelial neoplasia (CIN) 5, 6. Consider colposcopy for women with persistent inflammatory smears after appropriate treatment, particularly if:
- Two consecutive Pap smears show inflammation
- Clinical risk factors are present (early age at first intercourse, contact bleeding, cervical erosion)
- The patient is in a high-risk population
When Colposcopy Is NOT Indicated
Colposcopy is not recommended for:
- Initial finding of mild-moderate inflammation on an otherwise normal Pap smear
- Asymptomatic women with normal cervical examination
- Inflammation that resolves on repeat testing
Patient Communication
Reassure patients that:
- Inflammatory cells on a normal Pap smear do not indicate cancer or precancerous changes
- This is a common, benign finding
- Routine screening intervals can continue unless severe inflammation is noted
- Any identified infections will be treated appropriately
The key is distinguishing between mild inflammation (which requires no action beyond routine follow-up) and severe inflammation with reactive changes (which warrants repeat testing in 3 months). This evidence-based approach balances appropriate surveillance against unnecessary interventions.